

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2024 June 15; 16(6): 2264-2866



**EDITORIAL**

- 2264 Dual primary gastric and colorectal cancer: The known hereditary causes and underlying mechanisms  
*Azer SA*
- 2271 Application of *Fusobacterium nucleatum* as a biomarker in gastrointestinal malignancies  
*Yu LC, Li YP, Xin YM, Mao M, Pan YX, Qu YX, Luo ZD, Zhang Y, Zhang X*
- 2284 T1 colorectal cancer management in the era of minimally invasive endoscopic resection  
*Jiang SX, Zarrin A, Shahidi N*
- 2295 Mixed neuroendocrine and adenocarcinoma of gastrointestinal tract: A complex diagnosis and therapeutic challenge  
*Shenoy S*
- 2300 Advancements in breath-based diagnostics for pancreatic cancer: Current insights and future perspectives  
*Tez M, Şahingöz E, Marth HF*
- 2304 Colorectal cancer and dormant metastases: Put to sleep or destroy?  
*Senchukova MA*

**REVIEW**

- 2318 Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer  
*Jiang YK, Li W, Qiu YY, Yue M*
- 2335 Research progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancer  
*Shu YJ, Lao B, Qiu YY*
- 2350 Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma  
*Yao M, Fang RF, Xie Q, Xu M, Sai WL, Yao DF*

**MINIREVIEWS**

- 2362 Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer  
*Zhou Y, Wu S, Qu FJ*
- 2380 Predicting the prognosis of hepatic arterial infusion chemotherapy in hepatocellular carcinoma  
*Wang QF, Li ZW, Zhou HF, Zhu KZ, Wang YJ, Wang YQ, Zhang YW*

- 2394 Unraveling colorectal cancer prevention: The vitamin D - gut flora - immune system nexus

Zhan ZS, Zheng ZS, Shi J, Chen J, Wu SY, Zhang SY

### ORIGINAL ARTICLE

#### Retrospective Cohort Study

- 2404 Unveiling the secrets of gastrointestinal mucous adenocarcinoma survival after surgery with artificial intelligence: A population-based study

Song J, Yan XX, Zhang FL, Lei YY, Ke ZY, Li F, Zhang K, He YQ, Li W, Li C, Pan YM

- 2419 Analysis of metabolic characteristics of metabolic syndrome in elderly patients with gastric cancer by non-targeted metabolomics

Zhang H, Shen WB, Chen L

#### Retrospective Study

- 2429 Predictive value of preoperative routine examination for the prognosis of patients with pT2N0M0 or pT3N0M0 colorectal cancer

Jing PF, Chen J, Yu ED, Miao CY

- 2439 Simplified liver imaging reporting and data system for the diagnosis of hepatocellular carcinoma on gadoteric acid-enhanced magnetic resonance imaging

Lyu R, Hu WJ, Wang D, Wang J, Ye YB, Jia KF

- 2449 Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

An TQ, Qiu H, Zhou QB, Zong H, Hu S, Lian YG, Zhao RH

- 2463 Development of a diagnostic nomogram for alpha-fetoprotein-negative hepatocellular carcinoma based on serological biomarkers

He L, Zhang C, Liu LL, Huang LP, Lu WJ, Zhang YY, Zou DY, Wang YF, Zhang Q, Yang XL

- 2476 Drug-eluting bead transarterial chemoembolization as neoadjuvant therapy pre-liver transplantation for advanced-stage hepatocellular carcinoma

Ye ZD, Zhuang L, Song MC, Yang Z, Zhang W, Zhang JF, Cao GH

- 2487 Association between *Helicobacter pylori* infection, mismatch repair, HER2 and tumor-infiltrating lymphocytes in gastric cancer

Castaneda CA, Castillo M, Bernabe LA, Sanchez J, Fassan M, Tello K, Wistuba II, Chavez Passiuri I, Ruiz E, Sanchez J, Barrera F, Valdivia D, Bazan Y, Abad-Licham M, Mengoa C, Fuentes H, Montenegro P, Poquioma E, Alatriza R, Flores CJ, Taxa L

- 2504 Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Pan D, Liu HN, Yao ZY, Chen XX, Li YQ, Zhu JJ, Han ZX, Qin XB

- 2520 Prediction of pathological complete response and prognosis in locally advanced rectal cancer

Xu YJ, Tao D, Qin SB, Xu XY, Yang KW, Xing ZX, Zhou JY, Jiao Y, Wang LL

**Observational Study**

- 2531** Extrahepatic cholestasis associated with paracoccidioidomycosis: Challenges in the differential diagnosis of biliopancreatic neoplasia  
*dos Santos JS, de Moura Arrais V, Rosseto Ferreira WJ, Ribeiro Correa Filho R, Brunaldi MO, Kemp R, Sankanrakutty AK, Elias Junior J, Bellissimo-Rodrigues F, Martinez R, Zangiacomini Martinez E, Ardengh JC*

**Clinical and Translational Research**

- 2541** Development of a novel staging classification for Siewert II adenocarcinoma of the esophagogastric junction after neoadjuvant chemotherapy  
*Zhang J, Liu H, Yu H, Xu WX*
- 2555** N6-methyladenosine methylation regulates the tumor microenvironment of Epstein-Barr virus-associated gastric cancer  
*Zhang Y, Zhou F, Zhang MY, Feng LN, Guan JL, Dong RN, Huang YJ, Xia SH, Liao JZ, Zhao K*
- 2571** Hepatocellular carcinoma: An analysis of the expression status of stress granules and their prognostic value  
*Ren QS, Sun Q, Cheng SQ, Du LM, Guo PX*
- 2592** Comprehensive analysis of clinical and biological value of *ING* family genes in liver cancer  
*Liu SC*
- 2610** Epidemiology and prognostic nomogram for locally advanced gastric signet ring cell carcinoma: A population-based study  
*Yu ZH, Zhang LM, Dai ZQ, Zhang MN, Zheng SM*
- 2631** Socioeconomic traits and the risk of Barrett's esophagus and gastroesophageal reflux disease: A Mendelian randomization study  
*Liu YX, Bin CL, Zhang L, Yang WT, An BP*

**Basic Study**

- 2646** Complement factor I knockdown inhibits colon cancer development by affecting Wnt/ $\beta$ -catenin/c-Myc signaling pathway and glycolysis  
*Du YJ, Jiang Y, Hou YM, Shi YB*
- 2663** Fine-needle aspiration technique under endoscopic ultrasound guidance: A technical approach for RNA profiling of pancreatic neoplasms  
*Seyfedinova SS, Freylikhman OA, Sokolnikova PS, Samochernykh KA, Kostareva AA, Kalinina OV, Solonitsyn EG*
- 2673** Comprehensive analysis of gene mutations and mismatch repair in Chinese colorectal cancer patients  
*Chen H, Jiang RY, Hua Z, Wang XW, Shi XL, Wang Y, Feng QQ, Luo J, Ning W, Shi YF, Zhang DK, Wang B, Jie JZ, Zhong DR*
- 2683** Action of circulating and infiltrating B cells in the immune microenvironment of colorectal cancer by single-cell sequencing analysis  
*Zhang JP, Yan BZ, Liu J, Wang W*

- 2697** Bidirectional effects of the tryptophan metabolite indole-3-acetaldehyde on colorectal cancer  
*Dai Z, Deng KL, Wang XM, Yang DX, Tang CL, Zhou YP*
- 2716** Sm-like 5 knockdown inhibits proliferation and promotes apoptosis of colon cancer cells by upregulating p53, CDKN1A and TNFRSF10B  
*Mo CJ, Deng XY, Ma RL, Zhu K, Shi L, Li K*
- 2727** Shi-pi-xiao-ji formula suppresses hepatocellular carcinoma by reducing cellular stiffness through upregulation of acetyl-coA acetyltransferase 1  
*Jian HY, Liang ZC, Wen H, Zhang Z, Zeng PH*
- 2742** Aspirin suppresses hepatocellular carcinoma progression by inhibiting platelet activity  
*Zhao LJ, Wang ZY, Liu WT, Yu LL, Qi HN, Ren J, Zhang CG*
- 2757** Circ\_0004592: An auxiliary diagnostic biomarker for gastric cancer  
*Kong S, Xu YH, Zheng M, Ju SQ, Shi HC*
- 2769** N-glycosylation of Wnt3 regulates the progression of hepatocellular carcinoma by affecting Wnt/ $\beta$ -catenin signal pathway  
*Zhang XZ, Mo XC, Wang ZT, Sun R, Sun DQ*

**SYSTEMATIC REVIEWS**

- 2781** Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer  
*Wang LM, Zhang WW, Qiu YY, Wang F*

**META-ANALYSIS**

- 2793** Meta-analysis of transarterial chemoembolization combined with cryoablation *vs* transarterial chemoembolization alone for  $\geq 5$  cm hepatocellular carcinoma  
*Cheng JF, Sun QL, Tang L, Xu XJ, Huang XZ*
- 2804** Dynamic contrast enhanced ultrasound in differential diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis  
*Esposito G, Santini P, Termite F, Galasso L, Mignini I, Ainora ME, Gasbarrini A, Zocco MA*
- 2816** Correlation analysis of interstitial maturity and prognosis of colorectal cancer: Meta-analysis  
*Liu ZJ, Zhang XW, Liu QQ, Wang SZ*

**SCIENTOMETRICS**

- 2826** Visualization analysis of research hotspots and trends on gastrointestinal tumor organoids  
*Wang G, Liu T, He WT*
- 2842** Trends and hotspots in gastrointestinal neoplasms risk assessment: A bibliometric analysis from 1984 to 2022  
*Fu QQ, Ma L, Niu XM, Zhao HX, Ge XH, Jin H, Yu DH, Yang S*

**LETTER TO THE EDITOR**

- 2862** New perspectives in prognostication of hepatocellular carcinoma: The role and clinical implications of transient receptor potential family genes

*Guan SH, Hu WJ, Wang XY, Gu YX, Zhou DH*

**RETRACTION NOTE**

- 2865** Retraction note to: RNA-binding protein CPSF6 regulates IBSP to affect pyroptosis in gastric cancer

*Wang XJ, Liu Y, Ke B, Zhang L, Liang H*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Samy Azer, FACC, MD, PhD, Professor, Department of Medical Education, King Saud University College of Medicine, Riyadh 11461, Saudi Arabia. azer2000@optusnet.com.au

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol)* is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJGO* mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

**INDEXING/ABSTRACTING**

The *WJGO* is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJGO* as 3.0; IF without journal self cites: 2.9; 5-year IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The *WJGO*'s CiteScore for 2023 is 4.2 and Scopus CiteScore rank 2023: Gastroenterology is 80/167; Oncology is 196/404.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Si Zhao*; Production Department Director: *Xiang Li*; Cover Editor: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

**LAUNCH DATE**

February 15, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Monjur Ahmed, Florin Burada

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

**PUBLICATION DATE**

June 15, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Dynamic contrast enhanced ultrasound in differential diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis

Giorgio Esposto, Paolo Santini, Fabrizio Termite, Linda Galasso, Irene Mignini, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco

**Specialty type:** Oncology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's classification**

**Scientific Quality:** Grade C

**Novelty:** Grade C

**Creativity or Innovation:** Grade C

**Scientific Significance:** Grade C

**P-Reviewer:** Luo XZ, China

**Received:** January 20, 2024

**Revised:** April 14, 2024

**Accepted:** April 28, 2024

**Published online:** June 15, 2024



**Giorgio Esposto, Fabrizio Termite, Linda Galasso, Irene Mignini, Maria Elena Ainora, Maria Assunta Zocco**, Department of CEMAD Digestive Disease Center, Fondazione Policlinico Universitario A Gemelli IRCCS, Catholic University of Rome, Rome 00168, Italy

**Paolo Santini**, Department of Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome 00168, Italy

**Antonio Gasbarrini**, Department of Medicina Interna e Gastroenterologia, CEMAD Digestive Disease Center, Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome 00168, Italy

**Corresponding author:** Maria Assunta Zocco, MD, PhD, Professor, Department of CEMAD Digestive Disease Center, Fondazione Policlinico Universitario A Gemelli IRCCS, Catholic University of Rome, Largo Gemelli 1, Rome 00168, Italy. [mariaassunta.zocco@unicatt.it](mailto:mariaassunta.zocco@unicatt.it)

### Abstract

#### BACKGROUND

Non-invasive differential diagnosis between hepatocellular carcinoma (HCC) and other liver cancer (*i.e.* cholangiocarcinoma or metastasis) is highly challenging and definitive diagnosis still relies on histological exam. The patterns of enhancement and wash-out of liver nodules can be used to stratify the risk of malignancy only in cirrhotic patients and HCC frequently shows atypical features. Dynamic contrast-enhanced ultrasound (DCEUS) with standardized software could help to overcome these obstacles, providing functional and quantitative parameters and potentially improving accuracy in the evaluation of tumor perfusion.

#### AIM

To explore clinical evidence regarding the application of DCEUS in the differential diagnosis of liver nodules.

#### METHODS

A comprehensive literature search of clinical studies was performed to identify the parameters of DCEUS that could relate to histological diagnosis. In accordance with the study protocol, a qualitative and quantitative analysis of the evidence was planned.

#### RESULTS

Rise time was significantly higher in HCC patients with a standardized mean

difference (SMD) of 0.83 (95% CI: 0.48-1.18). Similarly, other statistically significant parameters were mean transit time local with a SMD of 0.73 (95% CI: 0.20-1.27), peak enhancement with a SMD of 0.37 (95% CI: 0.03-0.70), area wash-in area under the curve with a SMD of 0.47 (95% CI: 0.13-0.81), wash-out area under the curve with a SMD of 0.55 (95% CI: 0.21-0.89) and wash-in and wash-out area under the curve with SMD of 0.51 (95% CI: 0.17-0.85). SMD resulted not significant in fall time and wash-in rate, but the latter presented a trend towards greater values in HCC compared to intrahepatic cholangiocarcinoma.

## CONCLUSION

DCEUS could improve non-invasive diagnosis of HCC, leading to less liver biopsy and early treatment. This quantitative analysis needs to be applied on larger cohorts to confirm these preliminary results.

**Key Words:** Dynamic contrast enhanced ultrasound; Hepatocellular carcinoma; Intracellular cholangiocarcinoma; Quantitative ultrasound; Liver cancer; Time-intensity curve

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Dynamic contrast enhanced ultrasound (DCEUS) is a novel technique that could help to overcome the diagnostic limits of standard contrast enhanced ultrasound. The parameters derived from the quantitative analysis of the time-intensity curve could give pivotal information upon the histotype of liver nodules. The aim of this paper is to explore clinical evidence regarding DCEUS application for differential diagnosis of liver nodules. To the best of our knowledge, this is the first systematic review and meta-analysis on this topic.

**Citation:** Esposito G, Santini P, Termite F, Galasso L, Mignini I, Ainora ME, Gasbarrini A, Zocco MA. Dynamic contrast enhanced ultrasound in differential diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. *World J Gastrointest Oncol* 2024; 16(6): 2804-2815

**URL:** <https://www.wjgnet.com/1948-5204/full/v16/i6/2804.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v16.i6.2804>

## INTRODUCTION

Primary liver cancer ranks as the sixth most diagnosed cancer globally and stands respectively as the third and second leading cause of cancer-related death and of premature cancer-related death worldwide. Its incidence is expected to rise by 55% in the next two decades, affirming it as a universal health burden[1]. Among primary liver cancers, hepatocellular carcinoma (HCC) constitutes roughly 80%-85% of cases[2], while intrahepatic cholangiocarcinoma (ICC) accounts for 15%-20% of all primary liver malignancies[3,4].

Differential diagnosis between these histotypes is often challenging and seldom requires histological exam. In this context, imaging techniques that assess contrast enhancement patterns, particularly contrast-enhanced ultrasound (CEUS), have been pivotal in defining liver lesions detected incidentally[5,6]. Indeed, HCC often displays distinct vascular alterations, such as gradual decrease in portal blood flow and the development of new blood vessels, resulting in increased arterial supply[7]. The arterial phase hyperenhancement (APHE) followed by gradual wash-out during the portal-venous phase, serve as defining features of HCC, exhibiting a specificity that almost reaches 100%[8,9]. The American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) relies on these distinct vascular patterns to categorize the risk of malignancy in liver nodules of cirrhotic patients[10,11]. Nevertheless, HCC occasionally displays atypical features leading to a considerable number of patients requiring liver biopsy for diagnosis[12,13]. According to the CEUS LI-RADS non diagnostic categories are LR-M, LR-3, and LR-4[10].

Several studies have explored the diagnostic accuracy of CEUS for distinguishing HCC from ICC with a recent meta-analysis affirming a sensitivity of 92% (95% CI: 0.84-0.96), a specificity of 87% (95% CI: 0.79-0.92) and an AUC of 0.95 (95% CI: 0.93-0.97)[14]. In this meta-analysis three CEUS features suggestive of HCC were APHE, mild washout and late washout (> 60 s) (in accordance with what reported in European Association for the Study of the Liver Clinical Practice Guidelines), while the three CEUS features indicating ICC were arterial rim enhancement, marked washout and early washout (< 60 s). Subgroup analyses revealed that the diagnostic performance may be influenced by factors such as liver background: The diagnostic odds ratio for the non-cirrhotic group exhibited greater improvement (89.67, 95% CI: 12.77-629.94) compared to the cirrhotic group, suggesting that CEUS demonstrates a superior detection ability in the non-cirrhotic group compared to the cirrhotic group[14].

Despite the CEUS features described above, ICC may resemble patterns observed in HCC[15] and therefore, the diagnosis continues to rely exclusively on tumor biopsy[16].

Dynamic CEUS (DCEUS) with standardized software could help to overcome these obstacles, providing functional and quantitative parameters and potentially improving accuracy in the evaluation of tumor perfusion[4,17].

Although literature have started to explore DCEUS application in diagnosis of liver lesions[17,18], the small sample sizes of enrolled patients limit the findings in daily clinical practice.

This systematic review and meta-analysis aims to comprehensively consolidate existing literature data. Its primary focus is to isolate potential parameters derived from dynamic CEUS studies that could significantly enhance clinical practice for differential diagnosis of HCC, potentially reducing the requirement for more invasive diagnostic procedures.

### **Analysis of the DCEUS**

After CEUS evaluation, the captured clip is exported in digital imaging and communications in medicine format and then analyzed using specific analysis software, such as VueBox® (Bracco, Milan, Italy). The analysis entails delineation of a region of interest (ROI) that includes the identified liver lesion and a ROI that includes normal liver parenchyma. The software processes the time-intensity curves, deriving continuous parameters (Figure 1).

The perfusion parameters extracted from time-intensity curves provide a comprehensive assessment of blood volume, flow dynamics, and contrast agent behavior within the tissue (Figure 2).

Here is a breakdown of each parameter.

Peak enhancement (PE) measures the maximum intensity of the contrast agent within the tissue in arbitrary units (AU).

Wash-in area under the curve (WiAUC) represents the cumulative enhancement of the contrast agent during the initial phase of its entry into the tissue, measured in AU.

Wash-in rate (WiR) indicates the rate at which the contrast agent enters the tissue, calculated in AU per unit time. It reflects the speed of the contrast agent's accumulation during the initial phase.

Rise time (RT) measures the time taken for the contrast agent to reach its PE from its initial entry into the tissue, usually quantified in seconds (s).

Time to peak (TTP) signifies the duration taken for the contrast agent to reach its maximum enhancement within the tissue, measured in seconds from the start of the imaging.

Mean transit time local (mTTL) indicates the average time taken for contrast agents to pass through the tissue being analyzed. It is measured in seconds and is a representation of the average transit time of the contrast agent within the tissue.

Wash-out area under the curve (WoAUC) signifies the cumulative decrease in contrast agent concentration during the washout phase, measured in AU. This phase represents the decline or removal of the contrast agent from the tissue.

Wash-in and wash-out area under the curve (WiWoAUC) encompasses the total contrast agent exposure by combining the area under both the wash-in and wash-out phases of the time-intensity curve, measured in AU. It encapsulates the overall contrast agent behavior throughout the imaging duration.

Fall time (FT) is the time required to return from the PE to the baseline level.

Wash-out rate (WoR) indicates the rate at which the contrast agent leaves the tissue, calculated in AU per unit time. It reflects the speed of the contrast agent's regression during the portal and late phases.

Ratio of each parameter is defined as the percent change between the focal liver lesion and the surrounding parenchyma [*i.e.*, (ROI lesion-ROI parenchyma)/ROI parenchyma].

---

## **MATERIALS AND METHODS**

---

### **Research question**

A systematic literature review was conducted to answer the following research question: Can dynamic contrast enhanced ultrasound be used to improve the diagnostic accuracy of standard qualitative CEUS in diagnosis of liver cancer?

### **Protocol registration**


The study was conducted according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) [19,20] and synthesized with meta-analysis. The study protocol for this systematic review and meta-analysis was written and submitted to the International Register of Systematic Reviews (PROSPERO, ID: CRD4202349104) prior to the completion of the literature search.

### **Literature search strategy**


The search was conducted in the following electronic bibliographic databases: Medline (*via* PubMed), EMBASE (*via* Ovid), and Web of Science. To assure an adequate sensitivity, the search strategy only included terms related to the diagnostic technique being evaluated and the target population of patients affected by liver cancer. Therefore, three domains were combined, regarding DCEUS and HCC. The search string for each database can be consulted in the [Supplementary Table 1](#). The search was complemented by manually reviewing references of retrieved articles and the prior systematic reviews on this topic.

### **Selection criteria**

Studies were considered eligible if they met the following inclusion criteria: (1) Prospective and retrospective cohort studies; (2) Written in English; and (3) Describing patients with suspect liver cancer who had undergone a contrast enhanced ultrasound for diagnosis. Meeting abstracts and oral or poster communications at scientific congresses were excluded. The results of the literature search were merged, and duplicates were removed using EndNote™. Individual records were manually screened with title and abstract analysis by two independent reviewers (Esposito G and Termite



**Figure 1** A 66-year-old female patient with hepatocellular carcinoma LR-M. A: Contrast-enhanced ultrasound; B: Corresponding time-intensity curve of the lesion derived with VueBox® software. CEUS: Contrast-enhanced ultrasound.



**Figure 2** Time-intensity curve. FT: Fall time; mTTL: Mean transit time local; PE: Peak enhancement; RT: Rise time; TI: The point in time when the tangent of WIR intersects the x-axis; TO: The point in time when the tangent of the maximum decrease intersects the x-axis; TTP: Time to peak; WIAUC: Wash-in area under the curve; WIR: Wash-in rate; WoR: Wash-out rate; WOAUC: Wash-out area under the curve; WIWoAUC: Wash-in and wash-out area under the curve.

F). Any disagreement was resolved by discussion. Records considered appropriate were eligible for full-text analysis. Study selection, full-text analysis, and data extraction have been performed by two reviewers (Esposito G and Termite F). In the case of multiple records reporting on a single study, we focused on the most recent published paper in which the outcomes of the review were reported in the most exhaustive and complete way.

**Data extraction and data synthesis**

The following data were collected: Author, location, year of publication, study design, total number of patients, histology of liver cancer, DCEUS continuous parameters derived from time-intensity curves, type of contrast agent used, software used for analysis of time-intensity curves and confounding factors as reported in each study. Missing data were requested from study authors.

In accordance with the study protocol, a qualitative analysis of the evidence was planned. The results were summarized with a comprehensive summary table of study characteristics and baseline characteristics of participant patients (Tables 1 and 2).

Data synthesis was performed by dividing the selected studies into groups defined by tumor’s histology. The results were summarized with a comprehensive summary table of the time-intensity curve analysis (Table 3).

The quantitative synthesis of the data was carried out through analysis of the Hedges' g standardized mean difference (SMD) of each DCEUS parameter. This method is more conservative than simple mean difference analysis and accounts for the differences in the ultrasound machines used in the studies. Whenever the original paper did not report the results in terms of mean and standard deviation, the relative median and interquartile range were converted according to the indications of the Cochrane Library[21]. Heterogeneity was assessed by calculation of  $\tau^2$  and  $I^2$  statistics. The first account for the between-studies variance, while the second one represents the proportion of total variation across studies due to heterogeneity rather than chance. SMDs were meta-analyzed using a random effect model when the heterogeneity was high ( $I^2 > 50\%$ ) or very high ( $I^2 > 75\%$ ). When heterogeneity was moderate ( $I^2 < 50\%$ ) or low ( $I^2 < 25\%$ ), SMDs were meta-

**Table 1 Risk of bias assessment and concerns about applicability according to Quality Assessment of Diagnostic Accuracy Studies tool for quality assessment of prognostic accuracy studies**

Ref.	Risk of bias				Applicability concerns		
	Patients selection	Index test	Reference standard	Flow and timing	Patients selection	Index test	Reference standard
Ainora <i>et al</i> [5], 2023	Low	Unclear	Low	Low	Low	Low	Low
Dong <i>et al</i> [15], 2023	Unclear	Low	Low	Low	Low	Low	Low
Wildner <i>et al</i> [23], 2019	High	Unclear	Unclear	High	Low	Low	Low
Wildner <i>et al</i> [17], 2014	High	High	Low	High	Low	Low	Low

**Table 2 Study characteristics of included publications**

Ref.	Study design	Outcome	No. patients	Ultrasound contrast agent	Software for analysis of time-intensity curves
Ainora <i>et al</i> [5], 2023, Italy	Prospective	HCC vs ICC	82	SonoVue®	Vuebox®
Dong <i>et al</i> [15], 2023, China	Retrospective	HCC vs ICC	54	SonoVue®	Vuebox®
Wildner <i>et al</i> [23], 2019, Germany	Prospective	HCC vs ICC vs metastases vs FNH	148	SonoVue®	Vuebox®
Wildner <i>et al</i> [17], 2014, Germany	Prospective	HCC vs ICC	43	SonoVue®	Vuebox®

FNH: Focal nodular hyperplasia; HCC: Hepatocellular carcinoma; ICC: Intracellular cholangiocarcinoma.

**Table 3 Baseline patients' characteristics in the included publications**

Ref.	Age (yr)	Sex (male/female)	Origin of the study population	No. HCC	No. non HCC
Ainora <i>et al</i> [5], 2023	68 ± 11	55/27	Cirrhotic and non-cirrhotic patients	38	44
Dong <i>et al</i> [15], 2023	59.4 ± 8.6 (ICC) 60.9 ± 12.1 (HCC)	27/27	Non-cirrhotic patients	24	30
Wildner <i>et al</i> [23], 2019	63.8 ± 12.6	84/64	Cirrhotic and non-cirrhotic patients	41	107
Wildner <i>et al</i> [17], 2014	67	30/13	Cirrhotic and non-cirrhotic patients	23	20

HCC: Hepatocellular carcinoma; ICC: Intracellular cholangiocarcinoma.

analyzed using a fixed effect inverse variance model.

### Risk-of-bias assessment

Risk of bias of eligible studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool[22]. Risk-of-bias assessment was carried out by two authors (Esposito G and Termete F), and any disagreement between the two independent reviewers was resolved by discussion, with involvement of a third review author where necessary.

The number of studies was too small to allow a graphical assessment of publication bias by funnel plot or statistical assessment by Egger's test. However, all the identified studies showed a statistic difference between HCC and ICC patients in term of DCEUS parameters. Consequently, it cannot be excluded that this evidence could reflect the presence of a certain degree of unmeasurable publication bias.

### Outcomes

The main outcome of the current systematic review is the presence of a different distribution in DCEUS parameters between histological examination of liver cancer.

DCEUS parameters comprehend wash-out time (s), WoR ratio, FT (s), FT ratio, PE lesion, PE Ratio, WiAUC lesion, WiAUC ratio, RT lesion, mTTL lesion, mTTL ratio, TTP lesion, TTP ratio, WiR lesion, WiR ratio, WoAUC lesion, WoAUC ratio, WiWoAUC lesion, WiWoAUC ratio.

## RESULTS

### Study selection

Three biomedical databases were screened using the prespecified search methods on November 21, 2023, and a total of 696 studies were found (Medline *via* PubMed: 220, EMBASE *via* Ovid: 217, and Web of Science: 259). After removal of duplicates, 382 records underwent primary eligibility screening based on titles and abstracts. As a result, 25 papers met eligibility criteria for full-text analysis. 21 studies were excluded: 1 was only present as an abstract and 17 were excluded due to the absence of quantitative continuous variables to be analyzed with specific software. Three narrative reviews previously published were excluded from further analysis. Finally, 4 studies matched the predetermined eligibility requirements for this systematic review.

After a structured risk-of-bias assessment, all 4 original papers were included in the qualitative synthesis. [Figure 3](#) shows the PRISMA selection flow diagram that describes the study-selection process in detail.

### Risk-of-bias assessment

To evaluate the internal and external validity of each included study, a structured analysis of the risk of bias was carried out using the QUADAS-2 tool[22] for quality assessment of diagnostic accuracy studies ([Table 1](#)). It is noteworthy that risk-of-bias assessment evaluates each included study in the context of the research questions of the current systematic review and meta-analysis and does not analyze the general scientific worth or quality of the individual study.

Two studies were at high risk of bias in the patients selection domain; the exclusion criteria are not available in the paper of Wildner *et al*[17], while Wildner *et al*[23] did not exclude patients treated for HCC. Treatment, both pharmacological or physical (*i.e.*, transcatheter arterial chemoembolization or transarterial radioembolization), could lead to changes in the distribution of the contrast ultrasound agent and therefore could be a bias for the analysis of the time-intensity curves. Moreover, despite both studies were conducted prospectively, one did not include consecutive patients [17], while the other one did not specify whether patients were consecutive[23]. In the same domain, one study was categorized as having an unknown risk of bias, because it was not clear if patients were consecutive or not[15].

The index test domain was judged to be at low risk of bias for one study[15], although the question about the use of a prespecified threshold was ignored due to the absence of a validated cutoff for HCC diagnosis. Two studies were categorized as having an unknown risk of bias in the index test domain, because it was not specified whether the DCEUS parameters analysis was carried out blind to the reference standard (*i.e.*, histopathology)[5,23]. This analysis was clearly not blinded in one study, that was hence judged at high risk in the index test[17].

Three studies were judged to be at low risk of bias in the reference standard domain[5,15,17], while one study[23] had an unknown risk, because it was not clear if the reference standard was interpreted blind to the DCEUS evaluation.

The flow and timing domain was at high risk for bias in two studies, due to the absence of an appropriate interval between the index test and the reference standard[17,23]. Indeed, if patients are treated in the interval between DCEUS and liver biopsy, the distribution of the contrast agent could be altered. Moreover, in both studies patients did not receive the same reference standard, as some patients were diagnosed with radiological findings [x-ray micro-computed tomography (CT), magnetic resonance imaging (MRI), or CEUS] and not with histological exam.

The evaluation of concerns about applicability was found to be at low risk for each domain in all four studies[5,15,17,23].

A visual summary of distribution of risk of bias and applicability concerns across QUADAS-2 domains can be found in [Supplementary Figure 1](#).

### DCEUS for differential diagnosis of HCC: Qualitative summary

The four studies considered eligible for qualitative synthesis were homogenous in terms of study design, outcomes, type of contrast agent and software for time-intensity curve analysis ([Table 2](#)), while there was a certain grade of heterogeneity in the population included and in the ultrasound machines used for CEUS examination.

The baseline characteristics of patients included in each study are summarized in [Table 3](#). The number of study participants ranges from 43 to 148, for a total of 327 patients.

The four studies considered eligible for qualitative synthesis analyzed the time-intensity curves with specific software. The results of the measured continuous variables are summarized in [Table 4](#).


Ainora *et al*[5] included 82 consecutive patients candidate to biopsy of focal liver lesions. Patients undergone both ultrasound B mode and CEUS evaluation with 2.4 mL of SonoVue® (Bracco, Milan, Italy). The reference standard was histopathological examination.

Ultrasound B mode characteristics showed no statistically significant difference between HCC and ICC. CEUS displayed arterial homogenous hyperenhancement in 68.5% of HCC and 22.7% of ICC lesions, while one HCC nodule (2.6%) and 15 ICC nodules (34.1%) had rim hyperenhancement. The 89% of nodules showed portal or late phase wash-out with a mean value of 59.4 s ± 26.9 s in HCC and 45.4 s ± 17.2 s in ICC lesions ( $P = 0.01$ ). Marked wash-out was found in 28.9% (11/38) of HCC lesions, in contrast to 52.3% (23/44) of ICC lesions ( $P = 0.03$ ).

**Table 4** Dynamic continuous variables of hepatocellular carcinoma vs intracellular cholangiocarcinoma lesions in the included publications

	Ainora <i>et al</i> [5], 2023		Dong <i>et al</i> [15], 2023	
	HCC (n = 38)	ICC (n = 44)	HCC (n = 24)	ICC (n = 30)
Rise time lesion (s)	10.9 ± 3.8	8.1 ± 4.1	11.9 ± 5.3	7.5 ± 3.0
Fall time lesion (s)	37.5 ± 19.5	35.4 ± 23.9	27.7 ± 10.8	14.9 ± 5.9
mTTL lesion (s)	67.0 ± 52.0	42.9 ± 46.1	68.9 ± 32.4	42.2 ± 18.0
TTP lesion (s)	12.5 ± 4.3	9.1 ± 5.8	17.6 ± 9.6	12.8 ± 6.4
PE percent change	0.66 ± 1.35	-0.04 ± 1.38	1.28 ± 0.47	1.16 ± 0.90
WiR percent change	2.41 ± 3.96	1.32 ± 1.91	2.33 ± 1.19	2.38 ± 2.33
WiAUC percent change	-0.22 ± 0.72	-0.52 ± 0.36	0.79 ± 0.45	0.61 ± 0.51
WoAUC percent change	-0.11 ± 0.74	-0.41 ± 0.53	0.85 ± 0.53	0.53 ± 0.42
WiWoAUC percent change	-0.13 ± 0.70	-0.39 ± 0.39	0.83 ± 0.50	0.55 ± 0.44

HCC: Hepatocellular carcinoma; ICC: Intracellular cholangiocarcinoma; mTTL: Mean transit time local; TTP: Time to peak; PE: Peak enhancement; WiR: Wash-in rate; WiAUC: Wash-in area under the curve; WiWoAUC: Wash-in and wash-out area under the curve; WoAUC: Wash-out area under the curve.



**Figure 3** Preferred Reporting Items for Systematic Reviews and Meta-analyses study selection flow diagram.

CEUS clips were then analyzed with Vuebox® software and significant differences were seen in four blood volume parameters: PE ( $P < 0.03$ ), WiAUC, WoAUC and WiWoAUC ( $P < 0.01$ ).

When the authors considered the ratio between nodules and the surrounding parenchyma, PE and WiAUC were statistically higher in HCC respect to ICC; higher WiR values were also observed ( $P < 0.01$ ). On the other side, mTTL, which is associated with portal and late-phase wash-out, was statistically shorter for ICC compared to HCC ( $P = 0.03$ ). At univariate analysis PE ratio (OR, 0.62; 95%CI: 0.43–0.91,  $P = 0.01$ ) and WiR ratio (OR, 0.87; 95%CI: 0.78–0.98,  $P = 0.02$ )

were associated with histological diagnosis. At multivariate analysis PE ratio ( $P = 0.02$ ) was independent predictor of HCC or ICC. Other independent factors were liver cirrhosis ( $P < 0.01$ ) and shear-wave elastography ( $P = 0.01$ ). The authors proposed a score based on these three factors for differential diagnosis of liver cancer, with an area under the receiver operating characteristic (ROC) curve of 0.836.

Dong *et al*[15] retrospectively included 54 patients with histological diagnosis of ICC or HCC in non-cirrhotic liver. Patients prior to surgery or liver biopsy, were subjected to both ultrasound B mode and CEUS examination with 1.5 mL of SonoVue® (Bracco, Milan, Italy). The reference standard was histopathological examination. CEUS clips were analyzed with Vuebox® software.

On ultrasound B mode evaluation there were no significant differences in size between ICC and HCC. On CEUS examination, all HCC nodules showed hyperenhancement ( $P < 0.05$ ), while ICC displayed various enhancement patterns. As concerns wash-out, 83.3% of ICC had arterial phase wash-out, while only 15.7% of them had portal venous phase wash-out. On the opposite HCC showed a 41.7% portal venous phase wash-out and 16.7% late phase wash-out ( $P < 0.05$ ).

Time-intensity curve analysis revealed four parameters (RT, mTTL, TTP, and FT) that were statistically lower in ICC nodules compared to HCC ( $P < 0.05$ ). Moreover, both WoAUC and WiWoAUC ratios were statistically lower in the ICC patients ( $P < 0.05$ ). No other parameter showed a significant difference between the two groups. On ROC curve analysis, FT had an AUROC of 0.903 (95%CI: 0.823–0.982) with a derived cutoff value of 16.9 s (95.8% sensitivity, 73.3% specificity, 83.3% accuracy) for distinction between ICC and HCC nodules in non-cirrhotic liver.

The combined AUROC of the RT, mTTL, TTP, FT, WoAUC ratio and WiWoAUC ratio was 0.946 (95%CI: 0.888–1.000) with 86.7% sensitivity, 95.8% specificity, and 90.7% accuracy. Overall, the authors concluded that these results improved the diagnostic accuracy of CEUS alone.

Wildner *et al*[23] in 2019 included 148 patients with liver nodules undergoing liver biopsy or radiological diagnosis. 138 patients were diagnosed by histological exam, while the remaining 10 were diagnosed by typical findings in CT, MRI, or CEUS. Patients undergone both ultrasound B-mode evaluation and CEUS examination with 1.5 mL of SonoVue® (Bracco, Milan, Italy). CEUS clips were analyzed with Vuebox® software. PE had significantly higher values for HCC compared to metastasis. RT, mTTL, and FT showed no statistical difference among the described groups. WiWoAUC was significantly higher in HCC compared to metastasis.

Wildner *et al*[17] in 2014 included 43 consecutive patients with focal liver lesions subjected to liver biopsy or radiological diagnosis. The authors performed both ultrasound B-mode and CEUS evaluation with 1.2 mL of SonoVue® (Bracco, Milan, Italy). CEUS clips were analyzed with Vuebox® software. As concerns DCEUS, the wash-in parameters were not significantly different from HCC and ICC, while mTTL and FT were statistically lower in ICC [mTTL,  $P = 0.0209$ ; HCC ( $118.4 \text{ s} \pm 88.4 \text{ s}$ ) vs ICC ( $64.8 \text{ s} \pm 49.7 \text{ s}$ ); FT,  $P = 0.0433$ ; HCC ( $42.5 \text{ s} \pm 27.7 \text{ s}$ ) vs ICC ( $27.7 \text{ s} \pm 16.2 \text{ s}$ )]. Wash-out after PE was significantly higher in ICC compared to HCC at definite timepoints: 40 s after PE ( $P = 0.0001$ ), 80 s after PE ( $P = 0.0007$ ), 100 s after PE ( $P = 0.0029$ ), and 120 s after PE ( $P = 0.0181$ ).

### DCEUS for differential diagnosis of HCC: Meta-analysis

The quantitative synthesis focused on the mean distribution of each continuous variable of the time-intensity curve across the HCC and ICC groups. The SMDs, calculated as Hedges'  $g$  SMD, are reported in Figure 4. SMDs were meta-analyzed using a random effect model or a fixed effect inverse variance model when respectively the heterogeneity was high ( $I^2 > 50\%$ ) or very high ( $I^2 > 75\%$ ) and when heterogeneity was moderate ( $I^2 < 50\%$ ) or low ( $I^2 < 25\%$ ). RT was significantly higher in HCC patients with a SMD of 0.83 (95%CI: 0.48-1.18). Similarly, mTTL showed a statistically significant SMD of 0.73 (95%CI: 0.20-1.27); PE showed a statistically significant SMD of 0.37 (95%CI: 0.03-0.70); WiAUC showed a statistically significant SMD of 0.47 (95%CI: 0.13-0.81); WoAUC showed a statistically significant SMD of 0.55 (95%CI: 0.21-0.89); WiWoAUC showed a statistically significant SMD of 0.51 (95%CI: 0.17-0.85). On the other hand, SMD resulted not statistically significant in FT and WiR, but the latter presented a trend towards greater values in HCC compared to ICC.


A sensitivity analysis was conducted in the subgroup of patients who developed HCC or ICC in a non-cirrhotic liver. The SMDs, calculated as Hedges'  $g$  SMD, are reported in Supplementary Figure 2. In this subgroup, mTTL showed a statistically significant SMD of 0.91 (95%CI: 0.44-1.39), WoAUC showed a statistically significant SMD of 0.61 (95%CI: 0.15-1.07), WiWoAUC showed a statistically significant SMD of 0.59 (95%CI: 0.13-1.05), PE and WiAUC showed a non-significant SMD, although a trend was shown toward greater values in HCC compared to ICC. SMD resulted not statistically significant in RT and FT.

## DISCUSSION


In this meta-analysis we only included two studies, for a total of 136 patients. The exclusion of Wildner *et al*[23] in 2019 and Wildner *et al*[17] in 2014 from the quantitative synthesis is due to the heterogeneity and lack of data to be compared with the remaining two studies and to a high risk of bias.

The quantitative analysis of Ainora *et al*[5] and Dong *et al*[15] showed a statistical significance for RT, mTTL, PE, WiAUC, WoAUC, and WiWoAUC. In our analysis, these values are higher in HCC nodules compared to ICC nodules and these results are consistent with the contrastographic behavior described by Chen *et al*[14]. Their meta-analysis on the capability of CEUS in differential diagnosis between HCC and ICC showed indeed that HCC is associated with APHE, mild washout and late washout ( $> 60 \text{ s}$ ), while ICC is associated with arterial rim enhancement, marked washout and early washout ( $< 60 \text{ s}$ ). DCEUS could come into aid in this context, as it provides quantification software for standardized analysis of enhancement microvasculature kinetics[24].


**A Rise time (s)**




**B Fall time (s)**




**C mTTL (s)**




**D PE pc**



**E WiR pc**





**Figure 4 Standardized mean difference of dynamic contrast-enhanced ultrasound parameters.** A: Rise time; B: Fall time; C: Mean transit time local; D: Peak enhancement; E: Wash-in rate; F: Wash-in area under the curve; G: Wash-out area under the curve; H: Wash-in and wash-out area under the curve. mTTL: Mean transit time local; PE: Peak enhancement; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma; SD: Standard deviation; WiR: Wash-in rate; WiAUC: Wash-in area under the curve; WiWoAUC: Wash-in and wash-out area under the curve; WoAUC: Wash-out area under the curve.

The sensitivity analysis conducted in the subgroup of non-cirrhotic patients revealed a statistical significance for mTTL, WoAUC, and WiWoAU. Compared to the above-mentioned analysis, PE and WiAUC lost significance, although a trend was shown toward greater values in HCC compared to ICC. These differences could be both explained by the smaller number of patients included and by the different distribution of contrast agent in cirrhotic liver compared to non-cirrhotic ones.

Indeed, CEUS features indicative of HCC in non-cirrhotic liver manifest typically as APHE and relatively rapid wash-out in the portal venous phase[15]. These characteristics diverge from those observed in HCC in cirrhotic liver and align more closely with ICC. The observed microvascular behavior can be explained by the fact that HCC in cirrhotic liver primarily obtains nourishment from branches of the hepatic artery, with minimal reliance on portal branches.

Moreover, a rim-like hyperenhancement pattern is more commonly detected in ICC occurring in individuals with a non-cirrhotic liver background. In contrast, ICC developing in the context of liver cirrhosis may display complete hyperenhancement, resembling patterns observed in HCC[15].

This can be understood by the evidence that significantly increased fibrous stroma and necrosis (features responsible for the rim-like hyperenhancement) are more common in ICC cases without liver cirrhosis compared to those with cirrhosis. Conversely, ICC developing in cirrhotic conditions may exhibit sustained augmentation of vasculature due to the enlargement and dilation of arterial branches[25].

This meta-analysis has several limitations, mainly due to the small number of studies and patients included. Whereas literature lacks studies specifically designed to explore each of the above discussed variables, our results look promising and are to be intended solely as a starting point for future studies. Our aim and hope are that this paper could be used as a model to design protocols on larger cohorts and hopefully find a diagnostic tool to improve HCC non-invasive differential diagnosis.

## CONCLUSION

DCEUS could in future represent a valid tool for non-invasive diagnosis of HCC, possibly leading to less liver biopsy and early treatment. In our analysis numerous DCEUS parameters (PE, mTTL, RS, WiAUC, WoAUC, and WiWoAUC) were indeed statistically higher in HCC nodules compared to ICC ones. This meta-analysis is limited by the paucity of data found in current literature. Despite the lack of strong evidence, our results show that DCEUS could help to overcome the limits of CEUS alone for differential diagnosis of HCC with atypical features. The quantitative analysis of CEUS parameters needs to be implemented and studied on larger cohorts, in order to confirm and eventually consolidate these preliminary results.

## FOOTNOTES

**Author contributions:** Esposito G, Santini P, Termete F, Galasso L, and Mignini I were responsible for writing original draft preparation; Santini P was responsible for data analysis; Ainora ME and Zocco MA were responsible for writing review and editing; Gasbarrini A was responsible for supervision; Zocco MA proposed conceptualization; all authors have read and agreed to the published version of the manuscript.

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country of origin:** Italy

**ORCID number:** Giorgio Esposito [0009-0007-8296-168X](https://orcid.org/0009-0007-8296-168X); Irene Mignini [0000-0002-8192-631X](https://orcid.org/0000-0002-8192-631X); Maria Elena Ainora [0000-0001-5847-1065](https://orcid.org/0000-0001-5847-1065); Antonio Gasbarrini [0000-0003-4863-6924](https://orcid.org/0000-0003-4863-6924); Maria Assunta Zocco [0000-0002-0814-9542](https://orcid.org/0000-0002-0814-9542).

**S-Editor:** Luo ML

**L-Editor:** A

**P-Editor:** Zhao S

## REFERENCES

- Rumgay H**, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. *J Hepatol* 2022; **77**: 1598-1606 [PMID: [36208844](https://pubmed.ncbi.nlm.nih.gov/36208844/) DOI: [10.1016/j.jhep.2022.08.021](https://doi.org/10.1016/j.jhep.2022.08.021)]
- Motta BM**, Masarone M, Torre P, Persico M. From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention. *Cancers (Basel)* 2023; **15** [PMID: [38001718](https://pubmed.ncbi.nlm.nih.gov/38001718/) DOI: [10.3390/cancers15225458](https://doi.org/10.3390/cancers15225458)]
- Yang JQ**, Wang XG, Wu B. Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database. *Transl Cancer Res* 2023; **12**: 3007-3015 [PMID: [38130317](https://pubmed.ncbi.nlm.nih.gov/38130317/) DOI: [10.21037/tcr-23-1278](https://doi.org/10.21037/tcr-23-1278)]
- Pascale A**, Rosmorduc O, Duclos-Vallée JC. New epidemiologic trends in cholangiocarcinoma. *Clin Res Hepatol Gastroenterol* 2023; **47**: 102223 [PMID: [37797807](https://pubmed.ncbi.nlm.nih.gov/37797807/) DOI: [10.1016/j.clinre.2023.102223](https://doi.org/10.1016/j.clinre.2023.102223)]
- Ainora ME**, Cerrito L, Liguori A, Mignini I, De Luca A, Galasso L, Garcovich M, Riccardi L, Ponziani F, Santopaolo F, Pompili M, Gasbarrini A, Zocco MA. Multiparametric Dynamic Ultrasound Approach for Differential Diagnosis of Primary Liver Tumors. *Int J Mol Sci* 2023; **24** [PMID: [37239893](https://pubmed.ncbi.nlm.nih.gov/37239893/) DOI: [10.3390/ijms24108548](https://doi.org/10.3390/ijms24108548)]
- Vidili G**, Arru M, Solinas G, Calvisi DF, Meloni P, Sauchella A, Turilli D, Fabio C, Cossu A, Madeddu G, Babudieri S, Zocco MA, Iannetti G, Di Lembo E, Delitala AP, Manetti R. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis. *World J Gastroenterol* 2022; **28**: 3488-3502 [PMID: [36158272](https://pubmed.ncbi.nlm.nih.gov/36158272/) DOI: [10.3748/wjg.v28.i27.3488](https://doi.org/10.3748/wjg.v28.i27.3488)]
- Pinto E**, Pelizzaro F, Farinati F, Russo FP. Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies. *Medicina (Kaunas)* 2023; **59** [PMID: [37374319](https://pubmed.ncbi.nlm.nih.gov/37374319/) DOI: [10.3390/medicina59061115](https://doi.org/10.3390/medicina59061115)]
- Schellhaas B**, Bernatik T, Bohle W, Borowitzka F, Chang J, Dietrich CF, Dirks K, Donoval R, Drube K, Friedrich-Rust M, Gall C, Gittinger F, Gutermann M, Haenle MM, von Herbay A, Ho CH, Hochdoerffer R, Hoffmann T, Hüttig M, Janson C, Jung EM, Jung N, Karlas T, Klinger C, Kornmehl A, Kratzer W, Krug S, Kunze G, Leitlein J, Link A, Lottspeich C, Marano A, Mauch M, Moleda L, Neesse A, Petzold G, Potthoff A, Praktiknjo M, Rösner KD, Schanz S, Schultheiß M, Sivanathan V, Stock J, Thomsen T, Vogelpohl J, Vogt C, Wagner S, Wiegand C, Wiesinger I, Will U, Ziesch M, Zimmermann P, Strobel D. Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCU LAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma - A Prospective Multicenter DEGUM Study. *Ultraschall Med* 2021; **42**: e20 [PMID: [32717752](https://pubmed.ncbi.nlm.nih.gov/32717752/) DOI: [10.1055/a-1220-8561](https://doi.org/10.1055/a-1220-8561)]
- Meitner-Schellhaas B**, Jesper D, Goertz RS, Zundler S, Strobel D. Washout appearance of hepatocellular carcinomas using standardized contrast-enhanced ultrasound (CEUS) including an extended late phase observation - Real-world data from the prospective multicentre

- DEGUM study. *Clin Hemorheol Microcirc* 2023; **84**: 413-424 [PMID: 37334585 DOI: 10.3233/CH-231740]
- 10 **Kim TK**, Noh SY, Wilson SR, Kono Y, Piscaglia F, Jang HJ, Lyshchik A, Dietrich CF, Willmann JK, Vezeridis A, Sirlin CB. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. *Clin Mol Hepatol* 2017; **23**: 280-289 [PMID: 28911220 DOI: 10.3350/cmh.2017.0037]
- 11 **Shin J**, Lee S, Bae H, Chung YE, Choi JY, Huh YM, Park MS. Contrast-enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: A meta-analysis. *Liver Int* 2020; **40**: 2345-2352 [PMID: 32722894 DOI: 10.1111/liv.14617]
- 12 **Li F**, Li Q, Liu Y, Han J, Zheng W, Huang Y, Zheng X, Cao L, Zhou JH. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017. *Eur Radiol* 2020; **30**: 461-470 [PMID: 31297632 DOI: 10.1007/s00330-019-06317-2]
- 13 **Dong Y**, Wang WP, Lee WJ, Meloni MF, Clevert DA, Chammas MC, Tannapfel A, Forgiione A, Piscaglia F, Dietrich CF. Contrast-Enhanced Ultrasound Features of Histopathologically Proven Hepatocellular Carcinoma in the Non-cirrhotic Liver: A Multicenter Study. *Ultrasound Med Biol* 2022; **48**: 1797-1805 [PMID: 35710501 DOI: 10.1016/j.ultrasmedbio.2022.05.005]
- 14 **Chen Y**, Zhu Y, Chen K, Wang H, Zhang W, Bao J, Wang W. Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: A systematic review and meta-analysis. *Clin Hemorheol Microcirc* 2021; **79**: 293-309 [PMID: 33935070 DOI: 10.3233/CH-211145]
- 15 **Dong Y**, Chen S, Möller K, Qiu YJ, Lu XY, Zhang Q, Dietrich CF, Wang WP. Applications of Dynamic Contrast-Enhanced Ultrasound in Differential Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in Non-cirrhotic Liver. *Ultrasound Med Biol* 2023; **49**: 1780-1788 [PMID: 37156676 DOI: 10.1016/j.ultrasmedbio.2023.03.026]
- 16 **European Association for the Study of the Liver**. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. *J Hepatol* 2023; **79**: 181-208 [PMID: 37084797 DOI: 10.1016/j.jhep.2023.03.010]
- 17 **Wildner D**, Pfeifer L, Goertz RS, Bernatik T, Sturm J, Neurath MF, Strobel D. Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma. *Ultraschall Med* 2014; **35**: 522-527 [PMID: 25202903 DOI: 10.1055/s-0034-1385170]
- 18 **Guo HL**, Zheng X, Cheng MQ, Zeng D, Huang H, Xie XY, Lu MD, Kuang M, Wang W, Xian MF, Chen LD. Contrast-Enhanced Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. *J Ultrasound Med* 2022; **41**: 1213-1225 [PMID: 34423864 DOI: 10.1002/jum.15812]
- 19 **Page MJ**, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev* 2021; **10**: 89 [PMID: 33781348 DOI: 10.1186/s13643-021-01626-4]
- 20 **McInnes MDF**, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. *JAMA* 2018; **319**: 388-396 [PMID: 29362800 DOI: 10.1001/jama.2017.19163]
- 21 **Higgins JPT**, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. *Cochrane Handbook for Systematic Reviews of Interventions* version 6.4 (updated August 2023). United States: Bloomsbury, 2023
- 22 **Whiting PF**, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011; **155**: 529-536 [PMID: 22007046 DOI: 10.7326/0003-4819-155-8-201110180-00009]
- 23 **Wildner D**, Schellhaas B, Strack D, Goertz RS, Pfeifer L, Fiessler C, Neurath MF, Strobel D. Differentiation of malignant liver tumors by software-based perfusion quantification with dynamic contrast-enhanced ultrasound (DCEUS). *Clin Hemorheol Microcirc* 2019; **71**: 39-51 [PMID: 29865043 DOI: 10.3233/CH-180378]
- 24 **Dietrich CF**, Averkiou MA, Correias JM, Lassau N, Leen E, Piscaglia F. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. *Ultraschall Med* 2012; **33**: 344-351 [PMID: 22843433 DOI: 10.1055/s-0032-1313026]
- 25 **Yuan MX**, Li R, Zhang XH, Tang CL, Guo YL, Guo DY, Luo MK. Factors Affecting the Enhancement Patterns of Intrahepatic Cholangiocarcinoma (ICC) on Contrast-Enhanced Ultrasound (CEUS) and their Pathological Correlations in Patients with a Single Lesion. *Ultraschall Med* 2016; **37**: 609-618 [PMID: 25919414 DOI: 10.1055/s-0034-1399485]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

